PharmaTelevision - InDex Pharmaceuticals: Exciting Licensing Opportunity

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: InDex Pharmaceuticals: Exciting Licensing Opportunity

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

InDex Pharmaceuticals AB are one of a number of biotechnology companies to emerge from the renowned Karolinska Institute in Sweden. CEO, Svante Rasmuson and CSO Oliver von Stein discuss the companies approach to developing drugs using it’s DIMS (DNA immunomodulatory sequence) technology to address inflammatory bowel disease and other immune and inflammatory diseases such as asthma and COPD. Speaking at BIO 2009 where they presented their recent successful Phase 2 data they discuss their partnering strategies for the lead compound Kappaproct®, the other drugs in the pipeline and their suite of accompanying diagnostics for IBD.

Kappaproct® and other applications of InDex DIMS technology are available for license. For more information contact Adrian Dawkes, Managing Consultant PharmaVentures Ltd. | adrian.dawkes@pharmaventures.com | +44 (0)7931 428 487

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The origin of InDex Pharmaceuticals.

Fintan Walton:

Hello and welcome, we are here at Bio 2009 at the Annual Convention here in Atlanta. We are here to record a series of programs with leading Pharmaceutical and biotechnology companies to talk about the both their vision and what they are doing to build their organizations in tough economic times.

Fintan Walton:

Hello and welcome to PharmaVentures Business review here at Bio Atlanta. On this show I have Svante Rasmuson, who is the CEO of a company called InDex Pharmaceuticals based in Sweden. And Oliver von Stein who is the Chief Scientific Officer of InDex Pharmaceuticals. Welcome to the show.

Svante Rasmuson :

Thank you very much.

Svante Rasmuson :

Thank you.

Fintan Walton:

InDex Pharmaceuticals is a company that spinout of the Karolinska Institutet, could you tell us how the company was actually originated svanteAnd what it's key focus was at that time?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Oliver von Stein

Chief Scientific Officer

Svante Rasmuson , Chief Executive Officer Svante Rasmusonhas more than 20 years experience from both the life science sector and the financial industry, including earlier positions at Gambro and Alfred Berg Fondkommission. Since 1997 a partner in a financial strategy consulting firm with assignments and board representations in several Swedish Life Science companies. Medical School exam at Ume" University in 1986. Oliver von Stein , Chief Scientific Officer Oliver von Stein carried out his molecular biology PhD studies at the Institute of Genetics in Karlsruhe, Germany, and held a postdoctoral position at Centre of Genomics and Bioinformatics at Karolinska Institutet, Stockholm. Before joining InDex Pharmaceuticals, he worked as a project leader of expression profiling atMediGene AG, Munich, Germany.

InDex Pharmaceuticals

InDex Pharmaceuticals AB is a clinical stage biopharmaceutical company, a spinout fromKarolinska Institutet, which was founded in 2000 and is based in Stockholm, Sweden. It is a privately owned company with approximately 100 shareholders, including SEB Venture Capital and Life Equity Sweden. The company is building a leading immunotherapy franchise based on its TLR platform toll-like-receptors. It discovers and develops DIMS drugs DNA-based-immunomodulatory-sequence to treat diseases within a variety of therapeutic areas, includinginflammation and cancer. It has several proprietaryDIMS compounds in various stages of development, including Kappaproct, for the treatment of steroid resistent/dependent ulcerative colitis, currently in clinical Phase II studies. The company also has a niche strategy in multi-gene diagnostics. Its first diagnostic product DiBiCol, which offers a novel standard for gastrointestinal diseaseclassification, is being launched on the Swedish market.